The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

Clinical Trials Finder

Syndicate content

The Caring for Carcinoid Foundation offers its Clinical Trials Finder and Patient Resource. This resource will provide the neuroendocrine tumor community with the most up-to-date and comprehensive information on relevant clinical trials in the United States.

With this resource, patients and caregivers may learn about the availability and purpose of existing clinical trials, and access supplemental resources from the Food and Drug Administration, the American Cancer Society and the National Cancer Institute.

By using CFCF's Clinical Trials Finder, patients and caregivers can search our comprehensive neuroendocrine tumor database of clinical trials, which consists of all active clinical trials being conducted in the US for carcinoid, pancreatic neuroendocrine tumors and pheochromocytoma.

Visit our About Clinical Trials page to learn more. For additional information on clinical trials or help using this site, please contact CFCF at 617-948-2514 or info@caringforcarcinoid.org.

Titlesort icon Phase Status Conditions State
131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma (CHP-830) Enrolling Pheochromocytoma PA
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
Pheochromocytoma
TX
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer I/II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
TN
90Y-DOTA-tyr3-Octreotide With or Without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults. A Randomized, Placebo Controlled Phase II Trial With Dosimetry Guided Dosing II Not Recruiting Neuroendocrine Tumor IA
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors Enrolling Neuroendocrine Tumor WI
A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
NY
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors I Not Recruiting
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor
NY
TX
A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination With Sunitinib in Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors I Enrolling Pancreatic Neuroendocrine Tumor
IN
IA
A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer I/II Not Recruiting Pulmonary Carcinoid
AK
CA
KY
SC
TN
TX
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours III Not Yet Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
CA
FL
IL
IA
LA
MA
MN
NY
NC
PA
TN
TX
A Study Evaluating Ultratrace Iobenguane I 131(MIBG)in Patients With Malignant Pheochromocytoma/Paraganglioma II Not Recruiting Pheochromocytoma
CA
FL
IA
LA
MD
MO
NY
NC
PA
RI
TX
A Study of Axitinib in Advanced Carcinoid Tumors II Enrolling Carcinoid Tumor
CA
FL
A Study of IMC-A12 in Islet Cell Cancer II Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
CA
CO
FL
GA
IN
LA
OH
RI
TN
TX
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors II Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
FL
MA
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors II Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
IL
IA
KS
MI
MN
NE
NJ
OH
OK
PA
SD
WI
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome III Enrolling Carcinoid Tumor
CA
KY
LA
MS
NM
OR
PA
TN
VA
WI
An Investigation of Small Intestinal Carcinoid Carcinoma in Families II Enrolling Carcinoid Tumor NJ
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors I Enrolling Neuroendocrine Tumor TX
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors II Not Recruiting Neuroendocrine Tumor MA
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. II Not Yet Recruiting Pancreatic Neuroendocrine Tumor
MA
NY
OR
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors II Not Yet Recruiting
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor
MA
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors II
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor
MA
Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors II Not Yet Recruiting Pancreatic Neuroendocrine Tumor
CA
FL
Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer II Enrolling Pulmonary Carcinoid
AZ
CA
CO
CT
FL
GA
IL
IA
MD
MA
MI
MN
NE
NV
NJ
NM
NY
ND
OH
PA
VA
WV
WI
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low- or Intermediate-Grade Neuroendocrine Cancer I Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
TX

Get the facts on pancreatic neuroendocrine cancer

Tell Your Story

Sign-up for our e-Newsletter.

video

Latest Video

Check out the CFCF video library.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange